{"name":"VarmX B.V.","slug":"varmx-b-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Usual Pharmacological Care","genericName":"Usual Pharmacological Care","slug":"usual-pharmacological-care","indication":"Hypertension management","status":"phase_3"},{"name":"UFH","genericName":"UFH","slug":"ufh","indication":"Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"VMX-C001","genericName":"VMX-C001","slug":"vmx-c001","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Usual Pharmacological Care","genericName":"Usual Pharmacological Care","slug":"usual-pharmacological-care","phase":"phase_3","mechanism":"Usual Pharmacological Care involves the standard treatment approach for a medical condition.","indications":["Hypertension management"],"catalyst":""},{"name":"UFH","genericName":"UFH","slug":"ufh","phase":"phase_3","mechanism":"UFH acts as an anticoagulant by inhibiting the coagulation cascade, specifically by inactivating Factor Xa and thrombin.","indications":["Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism","Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"VMX-C001","genericName":"VMX-C001","slug":"vmx-c001","phase":"phase_3","mechanism":"VMX-C001 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOR0NtWWJLRU8zMnBZR294SE1jZF9mRVdXUDlVM1FlU1RNYTQ1Z0JfTVhhczEtcG9ualF2YlhiM3Z1RDUwZm1XUzNsNE1ud3JURVhFcGhXb3R6Ni10QU4yMlA4cklSRFFtQW1yeUVPR3lsNXJyRHFXWnZTU2xKWllWMFdtcUFZN2ViS01FUXhzcmFXMG5V?oc=5","date":"2025-09-16","type":"deal","source":"Kyabram Free Press","summary":"CSL in $757m deal with pioneering Dutch biotech - Kyabram Free Press","headline":"CSL in $757m deal with pioneering Dutch biotech","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}